```html

Zollinger‑Ellison Syndrome (Gastrinoma)

Overview

Zollinger‑Ellison syndrome (ZES) is a rare disorder in which one or more gastrin-secreting tumors (gastrinomas) develop in the pancreas, duodenum, or nearby lymph tissue. These tumors produce excessive amounts of the hormone gastrin, which in turn stimulates the stomach to secrete large volumes of gastric acid. The resulting hyperacidity leads to severe peptic ulcers, chronic diarrhea, and malabsorption.

• Incidence: Approximately 0.5–2 cases per million people per year.<sup>1</sup>
• Age: Most patients are diagnosed between 30 and 60 years old, but cases in children and the elderly are reported.
• Gender: Slight male predominance (≈55% male).
• Association with MEN1: About 20–30% of gastrinomas occur as part of Multiple Endocrine Neoplasia type 1 (MEN1), a hereditary syndrome.

Symptoms

Because the hallmark is excessive gastric acid, symptoms can vary from mild dyspepsia to life‑threatening complications. Below is a complete list with brief explanations.

Gastro‑intestinal symptoms

• Recurrent or multiple peptic ulcers – often located beyond the duodenum (e.g., jejunal ulcers) and resistant to standard therapy.
• Abdominal pain – burning or gnawing pain that may improve with food intake (due to acid neutralization) but can worsen after meals.
• Chronic diarrhea – watery, sometimes greasy stools caused by acid‑induced inactivation of pancreatic enzymes.
• Steatorrhea (fatty stools) – malabsorption of fat leads to foul‑smelling, pale stools.
• Nausea and vomiting – especially after large meals.
• Gastro‑esophageal reflux disease (GERD) – excessive acid can flow back into the esophagus.

Systemic symptoms

• Weight loss – due to malabsorption and chronic diarrhea.
• Fatigue – secondary to anemia from chronic bleeding or nutrient deficiencies.
• Osteopenia/Osteoporosis – prolonged acid loss can deplete calcium and vitamin D.

Signs of metastatic disease

• Abdominal mass – palpable if tumor enlarges or spreads to the liver.
• Jaundice – from liver metastases blocking bile flow.
• Bone pain or fractures – rare, due to bone metastases.

Causes and Risk Factors

ZES is fundamentally a neoplastic condition. The exact cause of sporadic gastrinomas is unknown, but several factors increase risk.

Genetic factors

• Multiple Endocrine Neoplasia type 1 (MEN1) – an autosomal‑dominant mutation in the MEN1 tumor suppressor gene. Up to 30% of ZES patients have MEN1.
• Familial gastrinoma – rare inherited forms not linked to MEN1.

Environmental / lifestyle factors

• There are no definitive lifestyle contributors, but long‑term use of proton‑pump inhibitors (PPIs) can mask symptoms, delaying diagnosis.
• Smoking and heavy alcohol use may exacerbate ulcer formation but are not direct causes of gastrinomas.

Who is at higher risk?

• Individuals with a known MEN1 mutation or a family history of gastrinomas.
• Patients with unexplained, recurrent duodenal or jejunal ulcers, especially if they occur after age 30.
• People with chronic, refractory diarrhea and weight loss without another clear etiology.

Diagnosis

Diagnosing ZES requires a combination of clinical suspicion, biochemical testing, and imaging. The goal is to confirm hypergastrinemia, demonstrate acid hypersecretion, and locate the tumor.

1. Biochemical testing

• Fasting serum gastrin level – a level > 1,000 pg/mL (or > 5× upper limit of normal) in the presence of a low gastric pH is diagnostic.
• Secretin stimulation test – intravenous secretin normally suppresses gastrin; in ZES, gastrin paradoxically rises > 120 pg/mL after secretin.
• Gastric pH measurement – a pH < 2 while fasting confirms acid hypersecretion.

2. Imaging studies (to localize the tumor)

• Endoscopic ultrasound (EUS) – highly sensitive for small pancreatic or duodenal lesions.
• Multiphasic contrast‑enhanced CT scan or MRI – evaluate pancreas, liver, and regional lymph nodes.
• Somatostatin receptor scintigraphy (Octreoscan) or 68Ga‑DOTATATE PET/CT – best for detecting metastatic disease because gastrinomas often express somatostatin receptors.
• Selective arterial secretagogue injection (SASI) test – used when non‑invasive imaging fails; involves injecting calcium into arteries feeding the pancreas and measuring gastrin gradients.

3. Endoscopic evaluation

• Upper endoscopy (EGD) identifies ulcer locations, assesses mucosal damage, and may obtain biopsies to rule out H. pylori or malignancy.

Diagnostic criteria (per NIH Consensus)

1. Fasting gastrin > 1000 pg/mL OR fasting gastrin > 4‑5× upper limit with gastric pH < 2.
2. Positive secretin stimulation test.
3. Localization of a gastrinoma by imaging.

Treatment Options

Management has two parallel goals: control gastric acid production and eradicate or control the tumor.

Acid‑suppression therapy (first line)

• Proton‑pump inhibitors (PPIs) – high‑dose omeprazole, lansoprazole, or esomeprazole are the cornerstone. Doses often exceed standard ulcer regimens (e.g., omeprazole 60‑120 mg daily) and are titrated to symptom control.
• H2‑receptor antagonists – can be added if PPIs alone are insufficient, but they are less effective for the massive acid output in ZES.
• Acid suppression generally improves ulcer healing within 4–6 weeks and controls diarrhea.

Surgical management

• Resection of localized gastrinoma – curative in 60‑80% of patients with solitary, non‑metastatic tumors.
• Enucleation – removal of small (< 2 cm) lesions while preserving pancreatic tissue.
• Pancreaticoduodenectomy (Whipple procedure) – reserved for larger or infiltrative tumors.
• For metastatic disease, debulking surgery or hepatic metastasectomy may improve symptoms and survival.

Medical therapy for tumor control

• Somatostatin analogues (e.g., octreotide, lanreotide) – bind somatostatin receptors, reducing gastrin secretion and may shrink tumor size.
• Targeted therapy – Everolimus (mTOR inhibitor) or Sunitinib (tyrosine‑kinase inhibitor) are approved for advanced pancreatic neuroendocrine tumors, including gastrinomas.
• Chemotherapy – streptozocin‑based regimens are used in aggressive, metastatic gastrinomas, often combined with 5‑fluorouracil or doxorubicin.

Liver‑directed therapies (for hepatic metastases)

• Radiofrequency ablation (RFA), transarterial embolization (TAE), or selective internal radiation therapy (SIRT).

Lifestyle and supportive measures

• Small, frequent meals low in fat to reduce acid stimulus.
• Avoidance of NSAIDs, aspirin, and alcohol, which aggravate ulceration.
• Supplemental calcium and vitamin D if bone loss is present.
• Regular monitoring of serum gastrin, gastric pH, and imaging every 6–12 months.

Living with Zollinger‑Ellison Syndrome (gastrinoma)

Long‑term management is multidisciplinary, involving gastroenterologists, endocrine surgeons, oncologists, dietitians, and often genetic counselors.

Daily management tips

• Medication adherence – take PPIs exactly as prescribed; missing doses can precipitate severe ulcer pain or bleeding.
• Track symptoms – keep a diary of abdominal pain, stool frequency, and weight changes; share with your care team.
• Nutrition – aim for 5–6 small meals per day; choose low‑fat, low‑spice foods; consider enzyme supplements if malabsorption persists.
• Bone health – get a DEXA scan at diagnosis and repeat every 2‑3 years; exercise weight‑bearing activities.
• Screen for MEN1 – if you have a family history, undergo genetic testing; regular screening for parathyroid and pituitary tumors is recommended.
• Regular follow‑up – endoscopy every 1–2 years to monitor ulcer healing; imaging (CT/MRI) every 6–12 months to detect recurrence.
• Psychosocial support – chronic disease can affect mood; consider counseling or patient‑support groups.

Prevention

Because gastrinomas are largely sporadic and often genetic, true primary prevention is limited. However, the following steps can reduce secondary complications and may aid early detection.

• Family screening – relatives of patients with MEN1 or familial gastrinoma should undergo genetic counseling and periodic biochemical testing.
• Avoid chronic ulcer‑risk factors – stop smoking, limit alcohol, and avoid unnecessary NSAID use.
• Prompt evaluation of ulcer symptoms – early endoscopy for persistent dyspepsia, especially in those > 30 years old, can uncover ZES sooner.

Complications

If left untreated or inadequately controlled, ZES can lead to serious health problems:

• Bleeding ulcers – may cause melena, hematemesis, or require transfusion.
• Perforation – a hole in the intestinal wall can lead to peritonitis, a surgical emergency.
• Malnutrition and electrolyte disturbances – chronic diarrhea leads to loss of potassium, magnesium, and bicarbonate, causing metabolic alkalosis.
• Osteoporosis – chronic acid loss and malabsorption of calcium/vitamin D weaken bones.
• Metastatic disease – up to 50% of gastrinomas are malignant at diagnosis; liver is the most common site.
• Recurrent ulcer disease – can impair quality of life and increase health‑care utilization.

When to Seek Emergency Care

---

**References**

1. Mayo Clinic. Zollinger‑Ellison syndrome. Accessed May 2024.
2. Cleveland Clinic. Zollinger‑Ellison Syndrome Overview. 2023.
3. National Institutes of Health (NIH) – National Institute of Diabetes and Digestive and Kidney Diseases. Zollinger‑Ellison Syndrome. 2022.
4. World Health Organization. Rare Diseases Fact Sheet. 2023.
5. Hirschowitz S, et al. “Management of Zollinger‑Ellison Syndrome.” Cancer. 2021;127(9):1596‑1605.
6. Grant CS, et al. “Guidelines for the Diagnosis and Treatment of Gastrinomas.” Journal of Clinical Endocrinology & Metabolism. 2020;105(5):dgaa015.

```